Allogeneic Hematopoietic Cell Transplantation Improves Outcome in Myelodysplastic Syndrome Across High-Risk Genetic Subgroups: Genetic Analysis of the Blood and Marrow Transplant Clinical Trials Network 1102 Study

PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) in patients with myelodysplastic syndrome (MDS) improves overall survival (OS). We evaluated the impact of MDS genetics on the benefit of HCT in a biological assignment (donor v no donor) study. METHODS: We performed targeted sequencing in...

Descripción completa

Detalles Bibliográficos
Autores principales: Versluis, Jurjen, Saber, Wael, Tsai, Harrison K., Gibson, Christopher J., Dillon, Laura W., Mishra, Asmita, McGuirk, Joseph, Maziarz, Richard T., Westervelt, Peter, Hegde, Pranay, Mukherjee, Devdeep, Martens, Michael J., Logan, Brent, Horowitz, Mary, Hourigan, Christopher S., Nakamura, Ryotaro, Cutler, Corey, Lindsley, R. Coleman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552956/
https://www.ncbi.nlm.nih.gov/pubmed/37607457
http://dx.doi.org/10.1200/JCO.23.00866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10552956/
https://www.ncbi.nlm.nih.gov/pubmed/37607457
http://dx.doi.org/10.1200/JCO.23.00866

Ejemplares similares